Kidney guidelines recommend calcimimetics as part of the multimodal management of CKD-MBD for the control of PTH and its associated prognostic benefits, while no recommendation currently exists for specific bone health endpoints such as fractures or BMD [2,6]. Here, PTH is linked to chronic kidney disease.